440 related articles for article (PubMed ID: 25157449)
1. Genetically engineered blood pharming: generation of HLA-universal platelets derived from CD34+ progenitor cells.
Figueiredo C; Blaszczyk R
J Stem Cells; 2014; 9(3):149-61. PubMed ID: 25157449
[TBL] [Abstract][Full Text] [Related]
2. HLA-universal platelet transfusions prevent platelet refractoriness in a mouse model.
Gras C; Schulze K; Goudeva L; Guzman CA; Blasczyk R; Figueiredo C
Hum Gene Ther; 2013 Dec; 24(12):1018-28. PubMed ID: 24090417
[TBL] [Abstract][Full Text] [Related]
3. Generation of HLA-deficient platelets from hematopoietic progenitor cells.
Figueiredo C; Goudeva L; Horn PA; Eiz-Vesper B; Blasczyk R; Seltsam A
Transfusion; 2010 Aug; 50(8):1690-701. PubMed ID: 20412529
[TBL] [Abstract][Full Text] [Related]
4. Generation of HLA Universal Megakaryocytes and Platelets by Genetic Engineering.
Figueiredo C; Blasczyk R
Front Immunol; 2021; 12():768458. PubMed ID: 34777386
[TBL] [Abstract][Full Text] [Related]
5. Generation of HLA-Universal iPSC-Derived Megakaryocytes and Platelets for Survival Under Refractoriness Conditions.
Börger AK; Eicke D; Wolf C; Gras C; Aufderbeck S; Schulze K; Engels L; Eiz-Vesper B; Schambach A; Guzman CA; Lachmann N; Moritz T; Martin U; Blasczyk R; Figueiredo C
Mol Med; 2016 Sep; 22():274-285. PubMed ID: 27262025
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of tumstatin in genetically modified megakaryocytes changes the proangiogenic effect of platelets.
Li J; Luo J; Luo YQ; Zhou M; Zhao L; Yao LJ; Dong H; Yang RN
Transfusion; 2014 Aug; 54(8):2106-17. PubMed ID: 24655355
[TBL] [Abstract][Full Text] [Related]
7. Platelets made HLA deficient by acid treatment aggregate normally and escape destruction by complement and phagocytes in the presence of HLA antibodies.
Meinke S; Sandgren P; Mörtberg A; Karlström C; Kadri N; Wikman A; Höglund P
Transfusion; 2016 Feb; 56(2):370-82; quiz 369. PubMed ID: 26442787
[TBL] [Abstract][Full Text] [Related]
8. HLA class I depletion by citric acid, and irradiation of apheresis platelets for transfusion of refractory patients.
Mirlashari MR; Vetlesen A; Nissen-Meyer LSH; Naper C; Tjønnfjord GE; Njerve IU; Ezligini F; Landmark BF; Meinke S; Sandgren P; Höglund P; Hetland G
Transfusion; 2021 Apr; 61(4):1222-1234. PubMed ID: 33580979
[TBL] [Abstract][Full Text] [Related]
9. Ex vivo large-scale generation of human platelets from cord blood CD34+ cells.
Matsunaga T; Tanaka I; Kobune M; Kawano Y; Tanaka M; Kuribayashi K; Iyama S; Sato T; Sato Y; Takimoto R; Takayama T; Kato J; Ninomiya T; Hamada H; Niitsu Y
Stem Cells; 2006 Dec; 24(12):2877-87. PubMed ID: 16960134
[TBL] [Abstract][Full Text] [Related]
10. Immune responsiveness against allogeneic platelet transfusions is determined by the recipient's major histocompatibility complex class II phenotype.
Sayeh E; Aslam R; Speck ER; Le-Tien H; Lazarus AH; Freedman J; Semple JW
Transfusion; 2004 Nov; 44(11):1572-8. PubMed ID: 15504162
[TBL] [Abstract][Full Text] [Related]
11. A future with less HLA: potential clinical applications of HLA-universal cells.
Figueiredo C; Blasczyk R
Tissue Antigens; 2015 Jun; 85(6):443-9. PubMed ID: 25864470
[TBL] [Abstract][Full Text] [Related]
12. C1q-binding anti-HLA antibodies do not predict platelet transfusion failure in Trial to Reduce Alloimmunization to Platelets study participants.
Jackman RP; Lee JH; Pei R; Bolgiano D; Lebedeva M; Slichter SJ; Norris PJ
Transfusion; 2016 Jun; 56(6):1442-50. PubMed ID: 27079754
[TBL] [Abstract][Full Text] [Related]
13. Transfusion-induced alloimmunization and platelet refractoriness in a mouse model: mechanisms and interventions.
Waterman HR; Kapp LM; Munday A; Odem-Davis K; Zimring JC
Transfusion; 2016 Jan; 56(1):91-100. PubMed ID: 26400622
[TBL] [Abstract][Full Text] [Related]
14. Proteomic study of apheresis platelets made HLA class I deficient for transfusion of refractory patients.
Mirlashari MR; Vetlesen A; Nissen-Meyer LSH; Stensland ME; Singh SK; Nyman TA; Hetland G
Proteomics Clin Appl; 2021 Nov; 15(6):e2100022. PubMed ID: 34510746
[TBL] [Abstract][Full Text] [Related]
15. Methods for the selection of platelet products for alloimmune-refractory patients.
Kopko PM; Warner P; Kresie L; Pancoska C
Transfusion; 2015 Feb; 55(2):235-44. PubMed ID: 25393955
[TBL] [Abstract][Full Text] [Related]
16. Human Leukocyte Antigen Class I Antibodies and Response to Platelet Transfusion in Patients Undergoing Liver Transplantation.
Wong M; Narra R; Selim M; Zimmerman MA; Kim J; Padmanabhan A; Hong JC
J Surg Res; 2020 Nov; 255():99-105. PubMed ID: 32543385
[TBL] [Abstract][Full Text] [Related]
17. Platelet alloimmunization after long-term red cell transfusion in transfusion-dependent thalassemia patients.
Lo SC; Chang JS; Lin SW; Lin DT
Transfusion; 2005 May; 45(5):761-5. PubMed ID: 15847666
[TBL] [Abstract][Full Text] [Related]
18. Pre-clinical development of a cryopreservable megakaryocytic cell product capable of sustained platelet production in mice.
Patel A; Clementelli CM; Jarocha D; Mosoyan G; Else C; Kintali M; Fong H; Tong J; Gordon R; Gillespie V; Keyzner A; Poncz M; Hoffman R; Iancu-Rubin C
Transfusion; 2019 Dec; 59(12):3698-3713. PubMed ID: 31802511
[TBL] [Abstract][Full Text] [Related]
19. Transfusion-related immunomodulation by platelets is dependent on their expression of MHC Class I molecules and is independent of white cells.
Aslam R; Speck ER; Kim M; Freedman J; Semple JW
Transfusion; 2008 Sep; 48(9):1778-86. PubMed ID: 18522705
[TBL] [Abstract][Full Text] [Related]
20. PAS-C platelets contain less plasma protein, lower anti-A and anti-B titers, and decreased HLA antibody specificities compared to plasma platelets.
Weisberg SP; Shaz BH; Tumer G; Silliman CC; Kelher MR; Cohn CS
Transfusion; 2018 Apr; 58(4):891-895. PubMed ID: 29473178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
